Valiant Organics Limited has informed the Exchange about Investor Presentation
VALIANTORG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Valiant Organics, a specialty chemicals manufacturer with 70,000 TPA capacity across 6 plants, filed its Q4 FY25 investor presentation. Consolidated revenue for FY25 stood at ₹7,188 Mn (vs ₹7,231 Mn in FY24), essentially flat year-on-year. EBITDA improved to ₹537 Mn with margins rising to 7.47% from 5.28% in FY24, though the company remained in the red with a consolidated loss of ₹34 Mn (vs ₹84 Mn loss in FY24). Revenue is heavily skewed to Dyes & Pigments (52%) and Agro Chemicals (25%), while Hydrogenation (47%) and Ammonolysis (28%) are the largest chemistry segments. The stock closed FY25 at ₹260.3, with a market cap of ~₹7,290 Mn and a 52-week range of ₹225–₹455. An ongoing capex on Ortho Amino Phenol (OAP) – currently fully imported into India – is in the trial run phase.
Margins showed a modest recovery in FY25 but profitability remains weak, with the stock trading well below its 52-week high. Investors should watch for OAP commercialization and any further margin improvement in coming quarters as key triggers.